Discover millions of ebooks, audiobooks, and so much more with a free trial

Only $11.99/month after trial. Cancel anytime.

Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids
Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids
Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids
Ebook4,602 pages33 hours

Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids

Rating: 0 out of 5 stars

()

Read preview

About this ebook

Neuropathology of Drug Addictions and Substance Misuse, Volume One: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids, Opioids and Emerging Addictions provides the latest research in an area that  shows that the neuropathological features of one addiction are often applicable to those of others. The book also details how a further understanding of these commonalties can provide a platform for the study of specific addictions in greater depth, all in an effort to create new modes of understanding, causation, prevention, and treatment.

The three volumes in this series address new research and challenges, offering comprehensive coverage on the adverse consequences of the most common drugs of abuse, with each volume serving to update the reader’s knowledge on the broader field of addiction, while also deepening our understanding of specific addictive substances. Volume One addresses tobacco, alcohol, cannabinoids, and opioids, with each section providing data on the general, molecular/cellular, and structural/functional neurological aspects of a given substance, along with a focus on the adverse consequences of addictions.

  • Provides a modern approach on the pathology of substances of abuse, offering an evidence based ethos for understanding the neurology of addictions
  • Fills an existing gap in the literature by proving a one-stop-shopping synopsis of everything to do with the neuropathology of drugs of addiction and substance misuse
  • Includes a list of abbreviations, abstracts, applications to other addictions and substance misuse, mini-dictionary of terms, summary points, 6+ figures and tables, and full references in each chapter
  • Offers coverage of preclinical, clinical, and population studies, from the cell to whole organs, and the genome to whole body
LanguageEnglish
Release dateMar 7, 2016
ISBN9780128003763
Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids

Related to Neuropathology of Drug Addictions and Substance Misuse Volume 1

Related ebooks

Biology For You

View More

Related articles

Related categories

Reviews for Neuropathology of Drug Addictions and Substance Misuse Volume 1

Rating: 0 out of 5 stars
0 ratings

0 ratings0 reviews

What did you think?

Tap to rate

Review must be at least 10 words

    Book preview

    Neuropathology of Drug Addictions and Substance Misuse Volume 1 - Victor R. Preedy

    Neuropathology of Drug Addictions and Substance Misuse

    Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids

    Editor

    Victor R. Preedy

    King’s College London, London, UK

    Table of Contents

    Cover image

    Title page

    Copyright

    List of Contributors

    Preface

    Acknowledgments

    Part I. Setting the Scene: Foundations for Understanding Substance Misuse and Their Effects

    Chapter 1. The Nervous System and Addictions: Essentials for Clinicians

    Introduction

    A Neuroanatomical Compass

    General Structure of the Neuroanatomical System

    Psychoactive Substances and the Brain

    The Neurobehavioral Facets of Addiction: From Recreational Use to Dependence

    Applications to Other Addictions and Substance Misuse: New Behavioral Disorders?

    Societal Impact of Substances

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 2. Pathophysiology-Based Neuromodulation for Addictions: An Overview

    Introduction

    Finding Targets for Neuromodulation Intervention

    Pathophysiology of Addiction

    Neuromodulation Techniques and Brain Network Alterations

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 3. Gateway Hypothesis of Addiction and Substance Misuse: The Role of Neurophysiology and Psychological Mechanisms

    Introduction

    Neurophysiological Mechanisms

    Transition to Addiction and Psychological Mechanisms

    Personality of the Drug User

    Conclusion

    Summary and Key Points

    Chapter 4. Children of Parents with Substance Use Disorder

    Introduction

    Models of Substance Use Disorder Vulnerability

    From Models to Studies of Neurobiology of Children with Familial Substance Use Disorder

    Neuroimaging Studies of Children with Familial Substance Use Disorder

    Future Directions

    Summary

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 5. Drugs of Abuse and the Internet

    Introduction

    Drugs Sold on the Internet

    Conclusion

    Definition of Terms

    Key Facts on the Internet

    Summary Points

    Chapter 6. Trauma and Neurological Risks of Addiction

    Introduction

    Overview of Typology of Trauma

    Neurobiology of Trauma

    Basic Neurobiology of Drug Use and Addiction

    Posttraumatic Stress and Cannabinoid Receptors

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 7. Emotional Self-Medication and Addiction

    Introduction

    ESM and Addiction in Humans

    PSM and ESM in Nonhuman Animals

    ESM Induced by Reward Loss

    Future Directions: Bridging ESM and SUDs

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts about Self-Medication

    Summary Points

    Chapter 8. The Neurobiology of Comorbid Drug Abuse in Schizophrenia and Psychotic Disorders

    Introduction

    Epidemiological Data

    Correlates of Comorbid Drug Abuse in Schizophrenia

    Neurobiology of Comorbid Drug Abuse

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of the Neurobiology of Comorbid Drug Abuse in Schizophrenia

    Summary Points

    Part II. Tobacco

    Section A. General Aspects

    Chapter 9. Nicotine Chemistry, Pharmacology, and Pharmacokinetics

    Introduction

    Nicotine Chemistry

    Nicotine Pharmacology

    Nicotine Pharmacokinetics

    Summary

    Afterword

    Definition of Terms

    Key Facts: PET Neuroimaging and Nicotine

    Summary Points

    Chapter 10. Tobacco-Related Mortality among Individuals with Alcohol or Drug Use Disorders

    Introduction

    Prevalence of Tobacco Use in AODUD Populations

    Tobacco-Related Diseases

    A Review of Tobacco-Related Mortality among Individuals with AODUD

    Best-Practice Guidelines Champion Smoking Cessation Integration into Addictions Treatment

    Barriers to Implementation of Concurrent Smoking Cessation with AODUD Treatment

    Staff Knowledge and Attitudes about Concurrent Smoking Cessation during AODUD Treatment

    Attitudes toward Smoking Cessation among AODUD Treatment Clients

    Effectiveness of Treatment for Nicotine Dependence Concurrent with AODUD Treatment

    Efforts to Increase Access to Nicotine-Dependence Treatment for AODUD Populations

    Other Policy Interventions to Reduce Tobacco-Related Mortality among Individuals with AODUD

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts of Contraband Tobacco Use in the AODUD Population

    Summary Points

    Chapter 11. Neurological Effects of Nicotine, Tobacco, and Particulate Matter

    Introduction

    Neurobiological Effects of Smoking Tobacco

    The Rewarding Effects of Nicotine

    Mechanism of Action: Nicotinic Acetylcholine Receptors

    Addictive Properties of Tobacco Smoke

    Tobacco Particulate Matter and Extracts

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Section B. Molecular and Cellular Aspects

    Chapter 12. Rho GTPases and Their Regulators in Addiction: A Focus on the Association of a β2-Chimaerin Polymorphism with Smoking

    Introduction

    Rho GTPases and Nicotine Addiction

    Chimaerins and Smoking

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Smoking Addiction

    Summary Points

    Chapter 13. Brain Orexin Receptors and Nicotine

    Introduction

    The Orexinergic System

    The Hypothalamus and Orexin Receptors

    Nicotine and Nicotinic Acetylcholine Receptors

    Nicotine and the Orexinergic System

    Human Studies of Nicotine on Orexin

    Paradigms of Nicotine Exposure to Replicate Clinical Conditions

    Nicotine Exposure on Orexin Expression

    Nicotine, Orexin, Addiction, and Reward

    Mechanisms Involved in Nicotine-Induced Orexin Expression Changes

    Conclusion and Future Directions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts Regarding the Orexinergic System

    Summary Points

    Chapter 14. Nicotine and Stimulatory Effects on 5-HT DRN Neurons

    Introduction

    Neuronal Nicotinic Acetylcholine Receptors

    The Dorsal Raphe Nucleus

    Effects of Nicotine on 5-HT DRN Neuron Firing Rate and 5-HT Release

    Behavioral Effects of Nicotine Mediated by Increases in Serotonin Release

    Concluding Remarks

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Microdialysis

    Summary Points

    Chapter 15. Critical Role of Cannabinoid CB1 Receptors in Nicotine Reward and Addiction

    Introduction

    Nicotine Reward and Dependence

    Endocannabinoid System and Signaling

    Cannabinoid Type 1 Receptors

    The Role of CB1 Receptors in Brain Reward Processing in Nicotine Administration

    Effects of CB1 Receptor Agonists and Antagonists on Nicotine Reward

    CB1 Receptor Ligands and nAChRs

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 16. Targets of Addictive Nicotine in the Central Nervous System and Interactions with Alcohol

    Introduction

    Effects of Nicotine

    Concurrent Effects of Nicotine with Alcohol

    Dual Effects of Nicotine

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Nicotine and Its Targets

    Summary Points

    Chapter 17. Cytochrome P450 and Oxidative Stress as Possible Pathways for Alcohol- and Tobacco-Mediated HIV Pathogenesis and NeuroAIDS

    Introduction

    Alcohol and NeuroAIDS

    Tobacco and NeuroAIDS

    Concluding Remarks

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of NeuroAIDS

    Summary Points

    Chapter 18. Nicotine and Neurokinin Signaling

    Introduction

    Tachykinin Genes and Gene Products

    Neuropeptide Distribution in the CNS

    Receptor Distribution in the CNS

    Neurokinin-Mediated Mechanisms in the CNS

    Tachykinins and Addiction Mechanisms

    Neurokinins and nicotine: cellular mechanisms

    Neurokinins and Nicotine: Regulation of Mood and Affect

    Neurokinins and the Symptoms of Nicotine Withdrawal

    Applications to Other Addictions and Substance Misuse

    Conclusions

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 19. Neurotransmitter Systems and the Nicotine Dependence-Induced Withdrawal Syndrome: Dopamine, Glutamate, GABA, Endogenous Opioids, Endocannabinoids, Noradrenaline, Arginine Vasopressin, Neuropeptide Y, MAO, CREB, and Corticotropin-Releasing Factor

    Introduction

    Nicotine-Induced Neuroadaptations

    Neural Basis of Nicotine Withdrawal

    Neurotransmitters and Mediator Systems Involved in Nicotine Withdrawal

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Summary Points

    Chapter 20. Genetic Findings on the Relationship between Smoking and the Stress System

    Introduction

    The HPA Axis and the Molecular Effects of GCs

    The Glucocorticoid Receptor-Coding Gene (NR3C1)

    Functional Aspects of NR3C1 Polymorphisms

    Effects of NR3C1 Polymorphisms on Smoking Behavior

    The MR Coding Gene

    Functional Aspects of NR3C2 Polymorphisms

    Effects of NR3C2 Polymorphisms on Smoking Behavior

    Potential for MR/GR Interactions beyond the Statistical Level

    Perspectives

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 21. Genetic Variants of μ Opioid Receptor and Its Interacting Proteins in Smoking: A Focus on OPRM1 A118G, ARRB2, and HINT1

    Introduction

    OPRM1 Polymorphisms

    OPRM1 and Smoking Behaviors

    Pharmacogenetic Studies of OPRM1 in Smoking Cessation

    ARRB2 and HINT1

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Smoking Related Phenotypes

    Summary Points

    Section C. Structural and Functional Aspects

    Chapter 22. Characterization of Cue-Induced Reinstatement of Nicotine-Seeking Behavior in Smoking Relapse: Use of Animal Models

    Introduction

    Rat Model of Smoking Relapse: Response Reinstatement Paradigm

    Cue-Induced Reinstatement of Nicotine-Seeking Responses

    Interactions of Nicotine Cue with Stress and Nicotine Priming

    Pharmacological Substrates Responsible for Cue-Induced Nicotine-Seeking Behavior

    Applications to Other Addiction and Substance Misuse

    Definition of Terms

    Key Facts of Cue-Induced Reinstatement of Nicotine-Seeking Behavior

    Summary Points

    Chapter 23. Effects of Environmental Enrichment on Nicotine Addiction

    Introduction

    Behavioral Effects of Nicotine in Enriched Animals

    Neural Effects of Enrichment on Nicotine Effects and Circuits

    Conclusions and Future Directions

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Environmental Enrichment

    Summary Points

    Chapter 24. Smokers with Severe Mental Illness

    Introduction

    Nicotine Addiction

    Why Do More People with Mental Illness Smoke?

    Facilitating Smoking Cessation

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Key Facts of Smoking among Those with Mental Illness

    Summary Points

    Chapter 25. Nicotine Dependence and Schizophrenia

    Introduction

    Epidemiology

    Clinical Features

    Etiological Relationship between Schizophrenia and Nicotine

    Management

    Application to Other Addictions and Substance Misuse

    Definition Of Terms

    Key Facts

    Summary Points

    Chapter 26. Unraveling the Role of the Amygdala in Nicotine Addiction

    Introduction

    The Role of Nicotine in Tobacco Addiction

    The Amygdala

    Nicotine Craving

    Functional Neuroimaging Studies on Cue-Induced Nicotine Craving

    Functional Neuroimaging Studies on Abstinence-Induced Craving

    Functional Neuroimaging Studies on Altered Emotion Processing in Smokers

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Nicotine Addiction

    Summary Points

    Chapter 27. Nicotine and Cognition: Effects of Nicotine on Attention and Memory Systems in Humans

    Introduction

    Nicotine and Attention

    Nicotine and Memory

    Long-term Effects of Nicotine on Cognition

    Indirect Effects of Nicotine

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Summary Points

    Chapter 28. The Role of Appetitive and Aversive Smoking Cues in Tobacco Use Disorder with a Focus on fMRI

    Introduction

    Reactivity to Appetitive Smoking Cues—Clinical Relevance

    Neural Correlates of Smokers to Appetitive Smoking Cues

    Reactivity to Aversive Smoking Cues—Clinical Relevance

    Neural Reactivity of Smokers to Aversive Smoking Cues

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Tobacco Use Disorder

    Summary Points

    Chapter 29. Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders

    Introduction

    Smoking and Cognitive Function in Healthy Subjects

    Smoking and Cognitive Function in Schizophrenia

    Smoking and Cognitive Function in Major Depressive Disorder

    Smoking and Cognitive Function in Bipolar Disorder

    Smoking and Cognitive Function in Obsessive-Compulsive Disorder

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 30. Tobacco Smoke Extract-Produced Behavioral Effects: Locomotor Sensitization and Self-Administration Studies

    Introduction: Tobacco Smoke Extracts in Research

    Behavioral Tests

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of History of Behavioral Nicotine/Tobacco Addiction Research

    Summary Points

    Chapter 31. The Psychological Threat of Mortality and Its Implications for Tobacco and Alcohol Misuse

    Introduction

    Psychological Defenses against Conscious Mortality Concerns: Implications for Substance Use

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts Concerning the Terror Management Health Model

    Summary Points

    Chapter 32. Nicotine Dependence and the Anterior Cingulate-Precuneus Pathway: Using Neuroimaging to Test Addiction Theories

    Physical Dependence

    Smoking and Brain Structure

    Learning Theories of Addiction

    Biological Theories of Addiction

    Hypothesis Testing

    What Impact Does This Have for Addiction Theorists?

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Physical Nicotine Dependence

    Summary Points

    Chapter 33. Neural Effects of Nicotine: Peripheral Sensory Systems and Experience-Dependent Neural Sensitization

    Introduction

    Rapid Neural Activation Induced by Intravenous Nicotine

    The Role of Peripheral Actions of Nicotine in Mediating Its Acute Neural Effects

    Experience-Dependent Changes in the Neural, Physiological, and Behavioral Effects of Nicotine

    The Role of Peripheral Actions of Nicotine in the Development of Nicotine-Induced Neural Sensitization

    General Discussion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Section D. Methods

    Chapter 34. Cotinine Urinalysis for Tobacco Use

    Introduction

    Pharmacokinetics and Pharmacodynamics

    Assays for Detection

    Research and Clinical Applications of Urine Cotinine Detection

    Sensitivity and Specificity Issues

    Applications to Other Addictions and Substance Misuse

    Comparison with Other Biomarkers of Tobacco Use

    Conclusions

    Definition of Terms

    Key Facts

    Summary Points

    Part III. Alcohol

    Section A. General Aspects

    Chapter 35. Ethanol Metabolism and Implications for Disease

    Introduction

    The Physical Properties of Ethanol

    International Variations in Alcohol Consumption

    Alcohol and the Burden of Disease

    Absorption and Distribution of Ethanol

    Metabolism of Ethanol

    Blood Ethanol Concentration

    Applications to Other Addictions and Substance Misuse

    Summary

    Definition of Terms

    Key Facts of Acetaldehyde

    Summary Points

    Chapter 36. Heavy Episodic Drinking or Binge Drinking: A Booming Consumption Pattern

    Introduction

    Definition of Binge Drinking

    Consequences on Health and Possible Early Markers

    Risk and Protection Factors Associated with BD

    Personality Traits, Circadian Typology, and BD

    Neuropsychological Impact of BD

    Future Research on Prevention and/or Treatment on BD

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Neuropsychology in Binge Drinkers

    Summary Points

    Section B. Molecular and Cellular Aspects

    Chapter 37. Alcohol and Endogenous Opioids

    Neuropeptides as Target System

    The Endogenous Opioid System

    The Opioid–Alcohol Link

    Endogenous Opioids in AUD

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Opioids

    Summary Points

    Chapter 38. Effects of Alcohol on Nicotinic Acetylcholine Receptors and Impact on Addiction

    Introduction

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Summary Points

    Chapter 39. Alcohol and Its Impact on Myelin

    Introduction

    The Myelination Process and Brain Development

    Composition of Myelin

    Pathophysiology of the Demyelination and Remyelination Processes in the CNS

    Alcohol Abuse and White Matter Disturbances

    Mechanisms of Alcohol-Induced Myelin Alterations

    Applications to Other Addictions and Substance Misuse

    Therapeutic Approaches

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 40. The Effects of Acute and Chronic Ethanol Exposure on GABAergic Neuroactive Steroid Immunohistochemistry: Relationship to Ethanol Drinking

    Introduction

    Immunohistochemistry Methodology and Strengths in Neuroactive Steroid Research

    GABAergic Neuroactive Steroids and Ethanol Interactions in Rats

    Neuroactive Steroids and Ethanol Drinking in Rats

    GABAergic Neuroactive Steroids and Ethanol Interactions in Mice

    Neuroactive Steroids and Ethanol Drinking in Nonhuman Primates

    Neuroactive Steroids and Ethanol Drinking in Humans

    GABRA2 Genetic Polymorphisms

    Genetic Polymorphisms and Neuroactive Steroids

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 41. Ethanol and Its Impact on the Brain’s Electrical Activity

    Alcohol Abuse and Its Neurological Consequences

    Influence of Alcohol on the Electrical Activity of the Brain

    CSD as a Tool to Study the Effects of Alcohol on the Brain

    Ethanol Influences CSD Propagation: The Role of Antioxidant Molecules

    Applications to Other Addictions and Substance Misuse

    Definitions and Explanations of Key Terms or Words Used in the Chapter

    Key Facts of Electrophysiology

    Summary Points

    Chapter 42. Alcohol and Neuroimmune Interactions

    Introduction

    Microglia

    Fetal Alcohol Spectrum Disorders

    Adolescent and College-Age Alcohol Consumption

    Adult Alcohol Consumption

    Neuroimmune Signaling

    Anti-inflammatory Therapeutics for Treatment of Alcohol Use Disorders

    Summary

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 43. Role of Glutamate Transport in Alcohol Withdrawal

    Introduction

    Glutamate Signaling Under Normal Physiological Conditions

    Glutamate Signaling During Alcohol Withdrawal

    Contribution of Genetic Variation in Glutamate Signaling to Alcohol Withdrawal Risk and Severity

    Preclinical Evidence for the Use of Ceftriaxone to Treat Acute AWS

    Applications to Other Addictions and Substance Misuse

    Summary and Conclusions

    Definition of Terms

    Key Facts on the Tricarboxylic Acid Cycle

    Summary Points

    Chapter 44. Ethanol, Vitamins, and Brain Dysfunction

    Brain Atrophy Affects Both White Matter and Gray Matter

    Functional Consequences

    Pathogenesis of Neurotoxicity in Alcoholics

    Liposoluble Vitamins

    Hydrosoluble Vitamins

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 45. Phospholipase D: A Central Switch in the Development of Fetal Alcohol Spectrum Disorder

    Fetal Alcohol Spectrum

    Phospholipases D

    Regulation of PLDs

    Enzymatic Reactions of PLDs

    Brain Cells and PLD

    PLD Function

    Effects of Ethanol In Vitro

    Effects of Ethanol and PLD Deletion In Vivo

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts of Phospholipases D

    Summary Points

    Chapter 46. N-Methyl-d-Aspartate Receptor Subunits and Alcohol

    Introduction

    Ethanol’s Actions at the NMDAR: Role in the Subjective and Behavioral Effects of Alcohol

    NMDAR Subunits and Ethanol

    Applications to Other Addictions and Substance Misuse

    Concluding Remarks

    Definition of Terms

    Key Facts of Glutamate

    Summary Points

    Chapter 47. Alcohol Dehydrogenase Alleles and Impact on Neuropathology

    Introduction

    Alcohol Metabolism

    ADH Alleles and Alcohol Use Disorders

    ADH Alleles and Effects on Neuropathology

    Fetal Alcohol Spectrum Disorders

    ADH Alleles and Neuropathology in FASD

    Role of the ADH Alleles in the Fetus

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Summary Points

    Chapter 48. ADH Cluster Genes, Genome-Wide Association Studies, and Alcohol Dependence

    Introduction

    Alcohol Metabolism and Major Genetic Factors

    Genome-Wide Association Study and ADH Gene Cluster

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts about Alcohol Dependence

    Summary

    Chapter 49. Neuropathology of Gene Expression during Alcohol Withdrawal

    Introduction

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts on the History of Alcohol Consumption

    Summary Points

    Chapter 50. The Quest of Candidate Gene in Alcohol Dependence: The Dopamine D2 Receptor (DRD2) Gene

    Introduction

    Molecular Genetics of Alcoholism

    Subtypes of Alcoholism Identified in Han Chinese

    Association Studies of the DRD2 Gene with Alcoholism Subtypes

    The DRD2 Gene and Temperament Interaction in Subtyped Alcoholism

    Summary

    DEFINITION of Terms

    Key Facts of Subtyped Alcoholism

    Summary Points

    Chapter 51. Acetaldehyde: A Reactive Metabolite

    Introduction

    Endogenous Aldehydes

    Exogenous Acetaldehydes

    Acetaldehyde Reactivity

    Protein Adduct Formation

    Damage to DNA

    Protein Carbonylation/Oxidation and Cytotoxicity

    Molecular Cytotoxic Mechanisms of Aldehydes

    Acetaldehyde or Ethanol?

    Human Health Risks

    Concluding Remarks

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Brain Metabolism

    Summary Points

    Section C. Structural and Functional Aspects

    Chapter 52. Cortical Morphology in Fetal Alcohol Spectrum Disorders: Insights from Computational Neuroimaging

    Introduction

    What Is Cortical Morphology?

    Cortical Morphology in Fetal Alcohol Spectrum Disorders

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Fetal Alcohol Syndrome Disorders

    Summary Points

    Chapter 53. Abnormalities of Cerebellar Structure and Function in Alcoholism and Other Substance Use Disorders

    Introduction

    Prevalence of Substance Use Disorders

    The Cerebellum and Addiction Connection

    Structure and Function of the Cerebellum

    Development of the Cerebellum

    Alcohol Use Disorders and the Cerebellum

    Cerebellar Abnormalities in SUD: Cause or Consequence?

    Cerebellar Structure and Function in Other Substance Use Disorders

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of the Cerebellum

    Summary Points

    Chapter 54. Brain Volumes in Adolescents with Alcohol Use Disorder

    Introduction

    Voxel-Based Morphometry and Related Methods of Structural Brain Imaging

    Hippocampal Volume Is Reduced in Adolescents with AUD

    Prefrontal Cortex Volume Is Differential in Adolescents with Alcohol Use Disorder

    Other Brain Regions Showing Differential Volumes in Adolescent AUD Compared to Controls

    Moderating and Mediating Factors—Gender, Psychiatric Comorbidities, Family History of Alcohol Abuse, Childhood Trauma

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts about Brain Volume Differences in Alcohol Use Disorder

    Summary Points

    Chapter 55. Central Pontine Myelinolysis in Alcoholism: An Osmotic Demyelination Syndrome

    Introduction

    Pathophysiology

    Pathology

    Neuroimaging

    Clinical Presentation

    Treatment and Prognosis

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Key Facts of the Blood–Brain Barrier

    Summary Points

    Chapter 56. The Role of Brain Glucocorticoid Systems in Alcohol Dependence

    Introduction

    Alcohol Activates the Hypothalamic–Pituitary–Adrenal Axis

    Chronic Alcohol Exposure Disrupts HPA Axis Function

    Role of Brain Glucocorticoid Receptor Activity in the Transition to Alcohol Dependence

    GR Structure, Chaperone Proteins, and Nuclear Cofactors

    Induction of Transcriptional Activation by GR

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts Related to Alcohol Misuse

    Summary Points

    Chapter 57. Neuropathobiology of Alcohol-Induced Cognitive Deficits

    Introduction

    Neuropathological Mechanisms Associated with Alcohol-Induced Cognitive Deficits

    Future Scope and Conclusions

    Definition of terms

    Key Facts on Alcohol-Induced Cognitive Deficit and Its Neuropathobiology

    Summary Points

    Chapter 58. Neuropathology in Neuropsychiatric Disorders Secondary to Alcohol Misuse

    Wernicke Encephalopathy

    Korsakoff Syndrome

    Marchiafava–Bignami Disease

    Alcohol Withdrawal Syndrome

    Alcohol-Related Dementia

    Alcoholic Cerebellar Degeneration

    Other Neuropsychiatric Disorders

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 59. Social Isolation and Ethanol Drinking: A Preclinical Model of Addiction Vulnerability in Males, but Not Females

    Introduction

    Sex Differences: From Acute Response to Alcohol to Neurobiological Consequences of Alcohol Dependence

    Epidemiology by Sex: Association with Alcohol Use Disorders

    Sex Differences: Neuroendocrine Responses in Vulnerable and Addicted Populations

    Social Isolation as a Model of Addiction Vulnerability in Male Rodents

    Hormones in Male and Female Rodents Exposed to Early Life Stress

    Sex Differences in Alcohol Models: Females Drink More!

    Models of an Addiction-Vulnerable Phenotype in Female Rats

    Sex Differences in Addiction Vulnerability: Future Directions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Consequences Following Adolescent Social Isolation Model in Male versus Female Rats

    Summary Points

    Section D. Methods

    Chapter 60. The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology

    Introduction

    Development of the ASSIST

    ASSIST-Lite Protocol

    Neuropathology as a Reason for Screening and Intervention

    Conducting a Brief Intervention with an Illicit Drug User

    Conclusion

    Key Facts

    Summary Points

    Part IV. Cannabinoids

    Section A. General Aspects

    Chapter 61. Overview of Cannabis Use, Misuse, and Addiction

    Introduction

    Acute and Long-term Effects of Cannabis Use

    Cannabis Misuse and the Risk of Addiction

    Translational Research on Cannabis Use in Animal Models

    Therapies for Cannabis Use and Withdrawal

    Is There a Potential Therapeutic Value for Medical Cannabis?

    Policy Changes in Cannabis Regulation

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of the Cannabinoid Tetrad Test

    Summary Points

    Chapter 62. An Overview of Major and Minor Phytocannabinoids

    Introduction

    Tetrahydrocannabinol Acid, Tetrahydrocannabivarinic Acid, and Cannabigerol Acid

    Cannabigerol

    Δ9-Tetrahydrocannabinol

    Tetrahydrocannabivarin

    Cannabidiol

    Cannabichromene

    Cannabinol

    β-Caryophyllene

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Summary

    Chapter 63. Treating the Phenomenon of New Psychoactive Substances: Synthetic Cannabinoids and Synthetic Cathinones

    Introduction

    Synthetic Cannabinoids

    Synthetic Cathinones

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Synthetic Cannabinoids and Psychosis

    Summary Points

    Section B. Molecular and Cellular Aspects

    Chapter 64. Role of Lipid Rafts and the Underlying Filamentous-Actin Cytoskeleton in Cannabinoid Receptor 1 Signaling

    Cannabinoid Receptor 1 Signaling: A Forceful Regulator of Neuronal Development and Function

    CB1 Signaling to the Major Effector Extracellular Signal-Regulated Kinase

    CB1 Signaling to ERK Emanates from Lipid Rafts

    Lipid Rafts, Filamentous-Actin Networks, and Microtubules Regulate CB1 Signaling and Localization

    Formation of CB1 Signaling Complexes and Transactivation of Tyrosine Kinase Receptors in Lipid Rafts

    Concluding Remarks

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of CB1

    Summary Points

    Chapter 65. Cannabinoid Agonists

    Introduction

    Endocannabinoids

    Phytocannabinoids: Δ9-Tetrahydrocannabinol

    Synthetic Cannabinoids

    Cannabinoid Agonists in the Clinic

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 66. Molecular Pharmacology of CB1 and CB2 Cannabinoid Receptors

    Introduction

    Introduction to Cannabinoid Receptor Research

    Overview of Endocannabinoid System Molecular Biology

    Overview of Cannabinoid Signaling in Cells

    Summary and Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Summary Points

    Chapter 67. Does Agonist Efficacy Alter the In Vivo Effects of Cannabinoids: Girl, Could We Get Much Higher?

    Introduction

    Cannabinoid Agonist Classification

    Herbal Incense: Not Your Parents’ Marijuana?

    Preclinical Studies

    Marijuana Dependence Studies in Humans

    Dependence and Withdrawal Studies in Animals

    Tolerance

    Drug Discrimination

    Reinforcement

    If Not Efficacy, What, Then?

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 68. Cannabis, Cannabinoid Receptors, and Stress-Induced Excitotoxicity

    Introduction

    Endocannabinoid System and Stress: A Bidirectional Relationship

    Stress and Cellular Damage/Death by Excitotoxicity

    Cannabinoid Receptor Activation and Stress-Induced Excitotoxicity

    Therapeutic Potential in Stress-Related Neuropsychopathologies

    Definition of Terms

    Key Facts of Excitotoxicity

    Summary Points

    Chapter 69. Cannabis, Endocannabinoid CB1 Receptors, and the Neuropathology of Vision

    Introduction

    Psychophysical Effects of Cannabinoids on Vision

    Electrophysiological Effects of Cannabinoids on Vision

    Conclusions and Future Directions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of the Cannabinoid System

    Summary Points

    Chapter 70. Cannabidiol and 5-HT1A Receptors

    Introduction

    Multiple Effects of Cannabidiol and Its Therapeutic Potential

    Cannabidiol and 5HT1A Receptors

    How Does Cannabidiol Interact with 5HT1A Receptors?

    Are All Cannabidiol Effects Mediated by 5-HT1A Receptors?

    Conclusion

    Application to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 71. CB1 Receptor-Mediated Signaling Mechanisms in the Deleterious Effects of Spice Abuse

    Introduction

    Cannabinoid Receptors

    Signal Transduction Mechanism of CB1R

    CB2R Signaling

    Spice Signaling

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Spice Products

    Summary Points

    Section C. Structural and Functional Aspects

    Chapter 72. Cannabis Use Disorders and Brain Morphology

    Introduction

    Nosology of Cannabis Use Disorder

    Neurocognitive Aspects of Cannabis Use Disorder

    Structural Neuroimaging Studies Investigating Cannabis Use Disorder

    Discussion

    Applications to Other Addictions and Substance Misuse

    Concluding Key Facts on the Association between Gray Matter and Cannabis Use Disorder

    Definition of Terms

    Key Facts of the Striatum

    Summary Points

    Chapter 73. Imaging Dopamine Alterations in Cannabis Dependence

    Introduction

    Imaging Methods Used to Study Dopamine in Humans

    Effect of Acute Cannabinoid Administration on the Dopamine System

    Effect of Chronic Cannabis Use on the Dopamine System

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts about Imaging the Dopamine System in Humans Using PET

    Summary Points

    Chapter 74. Cannabis and the Mesolimbic System

    The Dopaminergic Mesolimbic System

    Cannabinoids in the Reward Circuitry

    Cannabis Dependence

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of the Addictive Spines in the Nucleus Accumbens

    Summary Points

    Chapter 75. Role of the Endocannabinoid System and Major Cannabis Constituents in the Reconsolidation and Extinction of Rewarding Drug-Associated Memories

    Introduction

    Essential Aspects about Learning and Memory Processing

    Overview of the Endocannabinoid System

    Using the Conditioned Place Preference Paradigm to Investigate the Role of the Endocannabinoid System in Memory Reconsolidation and Extinction

    Role of the Endocannabinoid System in Learning and Memory Processing

    The Endocannabinoid System and Reconsolidation of Rewarding Drug-Related Memories

    The Endocannabinoid System and Reconsolidation of Aversive Memories

    Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Reconsolidation of Drug, Appetitive, and Aversive Memories

    Concluding Remarks

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Memory Reconsolidation

    Summary Points

    Chapter 76. Effects of Δ9-Tetrahydrocannabinol, Synthetic Cannabinoids, and Fatty Acid Amide Hydrolase Inhibitors on Mood and Serotonin Neurotransmission

    Introduction

    How to Assess If a Putative Drug Modulates Mood Using Animal Models

    Δ9-Tetrahydrocannabinol and Serotonin Firing Activity

    The Effect of WIN 55,212-2 on 5-HT Firing and Antidepressant-Like Activity

    Fatty Acid Amide Hydrolase Inhibition, 5-HT Firing, and Antidepressant-Like Activity

    Chronic Administration of CB1R Agonists in Adolescence and Adulthood: Implications for 5-HT Firing Activity

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 77. CB1 Cannabinoid Receptors and Aggression: Relationship to Cannabis Use

    Introduction

    The Endocannabinoid System

    Cannabis and Aggression in Humans

    Relation between Aggression and CB1 Receptor in Animal Studies

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Aggression

    Summary Points

    Chapter 78. Cannabis and Bipolar Manic Episodes

    Substance Use and Bipolar Disorder

    Childhood Trauma, Cannabis, and Bipolar Disorders

    Impact of Cannabis Use on Mania Phenomenology

    Impact of Cannabis Use on Bipolar Disorder Outcome

    Cannabis Use and Onset Manic Episode

    Cannabis Use and Psychosis

    Mechanisms Underlying Cannabis Use and Manic Symptoms

    Applications to Other Addictions and Substances Misuse

    Definition of Terms

    Key Facts of Mania and Bipolar Disorders

    Summary Points

    Chapter 79. White Matter, Schizophrenia, and Cannabis

    Introduction

    White Matter Changes in Schizophrenia

    White Matter Changes with Cannabis Use

    White Matter Changes with Cannabis Use in People with Schizophrenia

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 80. Electroencephalography and Cannabis: From Event-Related Potentials to Oscillations

    Introduction

    The Brain Cannabinoid System

    Electroencephalography

    Cannabinoids and ERPs

    Cannabinoids and Neural Oscillations

    Conclusion and Future Directions

    Applications to Other Addictions and Substance Misuse

    Defintion of Terms

    Key Facts of Cannabis and Electroencephalography

    Summary Points

    Part V. Opioids

    Section A. General Aspects

    Chapter 81. Street Level Heroin, an Overview on Its Components and Adulterants

    Introduction

    An Overview of Opiates

    Historical Review of Heroin

    A Focus on the Heroin Production Process

    Definition of Controlled Substances

    Controlled Substances Act Schedules

    Heroin Pharmacology

    What Does Heroin Look Like?

    Routes of Administration for Heroin

    Body Packing of Heroin

    Street Names and Slang Terms for Heroin

    Component Analysis of Heroin

    Medical Consequences of Street Heroin Abuse

    Concluding Remarks

    Application to Other Addictions and Substance Misuse

    Key Facts

    Chapter 82. Opioid Prescription Drug Abuse and Its Relation to Heroin Trends

    Introduction

    Trends

    Heroin Availability on the World Market

    Global Trends in Opioid and Opiate Abuse

    Opiate and Opioid Overdose Deaths

    United States

    Trends in Treatment for Opiates and Opioids

    Harm Reduction Response to Increasing Opioid and Heroin Abuse

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts

    Summary Points

    Section B. Molecular and Cellular Aspects

    Chapter 83. Corticotropin-Releasing Factor Signaling at the Intersection of Pain and Opioid Addiction

    Introduction

    The Addicted Phenotype

    Animal Models of Opioid Intake Escalation and Addiction

    Chronic Opioid Exposure and Hyperalgesia

    Opioid Addiction in Relation to Pain Management

    Shared Neural Mechanisms and Neurocircuitry Underlying Pain and Opioid Addiction

    Role of Corticotropin-Releasing Factor in Opioid-Induced Hyperalgesia and the Transition to Opioid Dependence

    Role of Corticotropin-Releasing Factor Signaling in Chronic Pain States

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts Related to Opioid-Induced Hyperalgesia and Addiction

    Summary Points

    Chapter 84. The Role of the δ Opioid Receptor Gene, OPRD1, in Addiction

    Introduction

    OPRD1 and Human Addiction

    Rodent Models and Addiction

    Drugs and δ Opioid Receptor Function

    Heterodimerization of μ and δ Opioid Receptors

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Pharmacogenetics of Addiction

    Summary Points

    Chapter 85. Genome-Wide Association Studies and Human Opioid Sensitivity

    Introduction

    Association Studies on Specific Candidate Genes for Human Opioid Sensitivity

    Genome-Wide Association Studies of Human Opioid Sensitivity

    Genome-Wide Association or Linkage Studies of Human Opioid Dependence

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 86. Opiate Receptors and Gender and Relevance to Heroin Addiction

    Introduction

    Opiate Receptors

    Classification and Localization of Opiate Receptors

    Structure of Opiate Receptors and Signal Transduction

    Tolerance, Dependence, and Addiction

    Gender Differences in the Pharmacological Effects of Opiates

    Gender Differences in Heroin Addiction

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Opiate Abuse

    Summary Points

    Chapter 87. Transcriptional Effects of Heroin and Methamphetamine in the Striatum

    Introduction

    Patterns of Gene Expression Regulated by the Acute Administration of Psychostimulants or Opioids

    Drug-Induced Regulation of Activity-Dependent Genes

    Activation of Stress-Related Genes by Drugs of Abuse

    Glucocorticoid Receptor-Dependent Genes Induced by Drugs of Abuse Are Expressed in Astrocytes

    Gene Expression Regulated by Chronic Administration of Psychostimulants or Opioids

    Chronic Methamphetamine and Heroin Treatment Activated Genes Enriched in the Nucleus Accumbens

    Transcriptional Effects of Chronic Methamphetamine and Heroin Treatment in the Striatum Display Similarity

    Regulation of Glucocorticoid Receptor-Dependent Genes in Response to Chronic Treatment

    Alteration of Circadian Genes by Chronic Methamphetamine and Heroin Treatment

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Polydrug Abuse

    Summary Points

    Section C. Structural and Functional Aspects

    Chapter 88. Neurological Abnormalities in Opiate Addicts

    Introduction

    Classification

    Causes of Neurological Disease in Opiate Addicts

    Neurological Abnormalities in Opiate Addicts

    Ischemic Stroke in Opiate Addicts

    Cerebral Bleeding in Opiate Addicts

    Epilepsy in Opiate Addicts

    Trauma

    Infections

    Cognitive Impairment

    Other CNS Abnormalities in Opiate Addicts

    PNS Disease

    Neurological Withdrawal Symptoms in Opiate Addicts and in Neonates

    CNS Imaging in Opiate Addicts

    Neuropathology in Opiate Addicts

    Premorbid Neurological Vulnerabilities Fostering the Development of Opiate Addiction

    Dependency of Neurological Abnormalities on the Mode of Opiate Administration, the Duration of Addiction, and the Opiate Dosage

    Neurological Complications during General Anesthesia

    Secondary Disease that Causes Tertiary Neurological Abnormalities

    Conclusions

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts

    Summary Points

    Chapter 89. Clinical and Preclinical Molecular Imaging in Chronic Pain—Implications for Analgesic Use and Misuse

    Introduction

    Pathophysiology Relevant to Pain Imaging

    Functional and Molecular Imaging of the Brain

    Functional and Molecular Imaging of Peripheral Structures

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Molecular Imaging

    Summary Points

    Chapter 90. Single-Photon-Emission Computed Tomography Studies with Dopamine and Serotonin Transporters in Opioid Users

    Introduction

    Dopamine

    Serotonin

    Discussion

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts Related to Opioid Dependency

    Summary Points

    Chapter 91. Personality Dimensions, Impulsivity, and Heroin

    Introduction

    Impulsivity and Heroin Dependence

    Temperament and Character Dimensions of Personality

    Relationships of Personality Dimensions with Impulsivity in Heroin Dependents

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Impulsivity, Temperament, and Character

    Summary Points

    Chapter 92. fMRI of Heroin and Ketamine Addiction

    Introduction

    Application to Types of Addictions

    Summary Points

    Chapter 93. Heroin-Induced Cerebrovascular Ischemia and Leukoencephalopathy: Role of Mitochondria

    Stroke and Heroin: A Chronological Review of Cases

    Heroin-Induced Leukoencephalopathy: A Chronological Review of Cases

    Discussion of Possible Pathophysiologies

    Hypoxia Is a Common Pathway to Induce Leukoencephalopathy

    Conclusion

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Spongiform Leukoencephalopathy

    Summary Points

    Chapter 94. The Hypothalamic–Pituitary–Adrenal Axis and Related Brain Stress-Response Systems and Heroin

    Introduction

    HPA Axis in Human Heroin Addiction and Rodent Models

    Arginine Vasopressin and V1b Receptor Systems

    Endogenous Opioid Systems

    Orexin and Dynorphin in the Lateral Hypothalamus

    Summary

    Definition of Terms

    Key Facts of Stress Responses in Opiate Addiction

    Summary Points

    Chapter 95. Accelerated Aging in Heroin Abusers: Readdressing a Clinical Anecdote Using Telomerase and Neuroimaging

    Introduction

    Neuropathology and Neuropsychology of Heroin Addiction

    Biological Indicators of Aging

    Heroin, Telomerase, and Neuroimaging: Crossroads between Molecular and Brain System Pathology

    A Paradigm Shift in the Understanding of Addiction Pathology

    Overall Summary

    Definition of Terms

    Summary Points

    Chapter 96. Attention Deficit Hyperactivity Disorder, Substance Use Disorders, and Heroin Addiction

    Introduction

    Applications to Other Addictions and Substance Misuse

    Conclusion

    Definition of Terms

    Key Facts of ADHD and Other Psychiatric Disorders

    Summary

    Chapter 97. Impaired Cognition Control and Inferior Frontal Cortex Modulation in Heroin Addiction

    Introduction

    Behavioral Impairments of Cognitive Control in Heroin Addiction

    Inferior Frontal Gyrus, Response Inhibition, and Heroin Addiction

    Applications to Other Addictions and Substance Misuse

    Conclusions

    Suggestions for Further Research

    Definition of Terms

    Key Facts of Cognitive Control Functions in Heroin Addiction and the Relation to the Inferior Frontal Gyrus

    Summary Points

    Section D. Methods

    Chapter 98. Assay for Opium Alkaloids

    Introduction

    Types of Biological Material Used for Determination of Opioids

    Sample Preparation for Bioanalysis of Opioids

    Detection and Quantification of Opioids in Biological Samples

    Review of Analytical Methods for Bioassay of Opium Alkaloids and Related Opioids

    Applications to Other Addictions and Substance Misuse

    Definition of Terms

    Key Facts of Bioassay of Opium Alkaloids and Opioid-Related Compounds

    Summary Points

    Chapter 99. Features of the Tridimensional Personality Questionnaire Associated with Heroin Users

    Introduction

    The Concepts of the TPQ and the TCI

    The TPQ Dimensions and Heroin Use

    Categorical Views of Personality in Relation to Heroin Use: the Switch from the TPQ

    The Autonomic Basis of Borderline Personality Trait and Heroin Use Disorder

    Applications to Other Addictions and Other Substance Misuse

    Conclusions

    Definition of Terms

    Key Facts of Personality Features in Heroin Users

    Summary Points

    Index

    Copyright

    Academic Press is an imprint of Elsevier

    125 London Wall, London EC2Y 5AS, UK

    525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

    50 Hampshire Street, 5th Floor, Cambridge, MA 02139, USA

    The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

    Copyright © 2016 Elsevier Inc. All rights reserved.

    No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

    This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

    Notices

    Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

    Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

    To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

    British Library Cataloguing-in-Publication Data

    A catalogue record for this book is available from the British Library

    Library of Congress Cataloging-in-Publication Data

    A catalog record for this book is available from the Library of Congress

    ISBN: 978-0-12-800213-1

    For information on all Academic Press publications visit our website at https://www.elsevier.com/

    Publisher: Mara Conner

    Acquisition Editor: Mara Conner

    Editorial Project Manager: Kathy Padilla

    Production Project Manager: Julia Haynes

    Designer: Matthew Limbert

    Typeset by TNQ Books and Journals

    www.tnq.co.in

    List of Contributors

    Ricardo Abadie-Guedes,     Departamento de Fisiologia e Farmacologia, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil

    Anissa Abi-Dargham,     Departments of Psychiatry and Radiology, Division of Translational Imaging, New York State Psychiatric Institute and Columbia University Medical Center, New York, NY, USA

    Osama A. Abulseoud

    National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA

    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA

    Jelena Acevska,     Faculty of Pharmacy, Institute of Applied Chemistry and Pharmaceutical Analysis, University Ss. Cyril and Methodius, Skopje, Republic of Macedonia

    Ana Adan

    Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain

    Institute for Brain, Cognition and Behavior (IR3C), Barcelona, Spain

    María A. Aguilar,     Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de València, Valencia, Spain

    Maryam Akhgari,     Department of Forensic Toxicology, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran

    Robert Ali,     Discipline of Pharmacology, School of Medical Sciences, The University of Adelaide, Adelaide, SA, Australia

    Amelia J. Anderson-Mooney,     Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA

    Muhammad Anees,     Department of Neurology and Neurosurgery, Lady Reading Hospital, Post Graduate Medical Institute, Peshawar, Khyber Pakhtunkhwa, Pakistan

    M. Carmen Arenas,     Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de València, Valencia, Spain

    Jamie Arndt,     Department of Psychology, University of Missouri – Columbia, Columbia, MO, USA

    Daniele Ascheri,     Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Turin, Torino, Italy

    Nida Ashraf,     Aga Khan University, Karachi, Pakistan

    Maxie Ashton,     The Adelaide Clinic, Gilberton, SA, Australia

    Olga Asimaki,     Basic Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

    Jean-Michel Aubry,     Mood Disorders Unit, Division of Psychiatric Specialties, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland

    Harinder Aujla,     Department of Psychology, University of Winnipeg, Winnipeg, MB, Canada

    A. George Awad,     Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, Canada

    Mahmoud A. Awara,     Dalhousie University, Halifax, NS, Canada

    Ana Bagues,     A. Farmacología y Nutrición, Departamento de Ciencias Básicas de la Salud. Unidad Asociada de I+D+i al CSIC, Rey Juan Carlos University, Alcorcón, Madrid, Spain

    Yatan P.S. Balhara,     Department of Psychiatry & National Drug Dependence Treatment Centre, WHO Collaborating Centre on Substance Abuse, All India Institute of Medical Sciences, New Delhi, India

    Francis Bambico

    Neurobiological Psychiatry Unit, McGill University, Montreal, QC, Canada

    Centre for Addiction and Mental Health, University Toronto, Toronto, ON, USA

    Laura Barrio-Real,     Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Selena E. Bartlett,     Addiction Neuroscience and Obesity Group, Institute of Health and Biomedical Innovation, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD, Australia

    Balapal S. Basavarajappa

    Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA

    Department of Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University, New York, NY, USA

    Aniruddha Basu,     Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India

    Claiton H.D. Bau,     Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

    Matthew C. Beattie,     Department of Psychiatry & Pharmacology, Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC, USA

    Benjamin Becker,     Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany

    Anton L. Beer,     Institut für Psychologie, Universität Regensburg, Regensburg, Germany

    Deepak Behera,     Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA

    Irina Benaiges,     Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain

    Dessa Bergen-Cico,     Department of Public Health, Syracuse University, Syracuse, NY, USA

    Susan E. Bergeson,     Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA

    Wade H. Berrettini,     Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Leandro J. Bertoglio,     Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil

    Charles S. Bockman,     Department of Pharmacology, Creighton University School of Medicine, Omaha, NE, USA

    Stefan Borgwardt,     Department of Psychiatry (UPK), University of Basel, Basel, Switzerland

    Josiane Bourque

    Department of Psychiatry, University of Montreal, Montreal, QC, Canada

    GRIP, Centre de recherche CHU Ste-Justine, Montreal, QC, Canada

    Muge Bozkurt,     Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey

    Katharine Alexandra Brennan,     School of Psychology, Victoria University of Wellington, Wellington, New Zealand

    Hilary Briggs,     The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA

    Samanth J. Brooks,     Department of Psychiatry and Mental Health, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

    Rachel Picada Bulcão,     Instituto Médico Legal, Polícia Científica, Curitiba (PR), Brazil

    Ute Burkhardt,     Department of Pharmacology, Goethe University Frankfurt, Frankfurt, Germany

    Tracy R. Butler,     Department of Psychology, University of Dayton, Dayton, OH, USA

    Eduardo Rodrigues Cabrera,     Instituto Médico Legal, Polícia Científica, Curitiba (PR), Brazil

    Daniela Caldirola,     Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, Department of Clinical Neurosciences, Albese con Cassano, Italy

    Russell C. Callaghan

    Northern Medical Program, University of Northern British Columbia (UNBC), Prince George, BC, Canada

    Human Brain Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada

    Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Elza Callegari,     Faculdade de Farmácia, Instituto de Ciências Biológicas, Universidade de Passo Fundo, Passo Fundo (RS), Brazil

    María J. Caloca,     Institute of Molecular Biology and Genetics, Spanish National Research Council (CSIC), University of Valladolid School of Medicine, Valladolid, Spain

    Alline C. Campos,     Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil

    Carla Cannizzaro,     Department of Sciences for Health Promotion and Maternal Care, School of Medicine, University of Palermo, Palermo, Italy

    Gavin Cape,     Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Benjamin L. Carnell,     The Adelaide Clinic, Gilberton, SA, Australia

    Javier R. Caso,     Department of Pharmacology, Faculty of Medicine, University Complutense, Madrid, Spain

    Lucas Henrique Cendron,     Faculdade de Farmácia, Instituto de Ciências Biológicas, Universidade de Passo Fundo, Passo Fundo (RS), Brazil

    Yun-Hsuan Chang

    Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan

    Department of Psychiatry, College of Medicine, National Cheng Kung University

    Gordon L.F. Cheng

    Laboratory of Neuropsychology, The University of Hong Kong, Pokfulam, Hong Kong

    Laboratory of Cognitive Affective Neuroscience, The University of Hong Kong, Pokfulam, Hong Kong

    Institute of Clinical Neuropsychology, The University of Hong Kong, Pokfulam, Hong Kong

    Kao Chin Chen,     Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    Kanwaljit Chopra,     Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study Panjab University, Chandigarh, India

    Tony C.H. Chow,     Schools of Biomedical Sciences and Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China

    Rachael Cico,     Columbia University, New York, NY, USA

    Jason B. Cook,     Department of Psychiatry & Pharmacology, Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC, USA

    Maurizio Coppola,     Department of Addiction, ASL CN2, Alba, Italy

    Jose A. Cortes-Briones

    Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA

    Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA

    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

    Janna Cousijn,     Department of Developmental Psychology, University of Amsterdam, The Netherlands

    Richard C. Crist,     Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Candice E. Crocker

    Department of Psychiatry, Dalhousie University, Halifax, NS, Canada

    Division of Neurology, Department of Medicine, Dalhousie University, Halifax, NS, Canada

    Kirsty Danielson

    School of Biological Sciences, Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand

    Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA

    Miguel Dasilva,     Faculty of Life Sciences, University of Manchester, Manchester, UK

    Malay Dave,     Department of Psychiatry, Jagjivanram Western Railways Hospital, Mumbai, Maharashtra, India

    Mariella De Biasi

    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    Department of Neuroscience, University of Pennsylvania, Philadelphia, PA, USA

    Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Cristiane R. de Carvalho,     Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil

    François De Guio,     Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1161 INSERM, Paris, France

    Dirk De Ridder,     Section of Neurosurgery, Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Sonia Dhiman,     Chitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India

    Giuseppina Diaferia,     Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, Department of Clinical Neurosciences, Albese con Cassano, Italy

    Marco Diana,     Department of Drug Sciences, School of Pharmacy, University of Sassari, Sassari, Italy

    Joseph R. DiFranza,     Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, MA, USA

    Aneta Dimitrovska,     Faculty of Pharmacy, Institute of Applied Chemistry and Pharmaceutical Analysis, University Ss. Cyril and Methodius, Skopje, Republic of Macedonia

    Le-Anh Dinh-Williams

    Department of Psychiatry, University of Montreal, Montreal, QC, Canada

    Centre de recherche de l’Institut universitaire en santé mentale de Montréal, Montreal, QC, Canada

    Maja Djurendic-Brenesel,     Institute of Forensic Medicine, Clinical Center Vojvodina, Novi Sad, Serbia

    Jonathan N. Dodd,     Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

    Neil C. Dodge,     Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA

    Paul D. Drew,     Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Rene Drucker Colín,     Departamento de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico DF, Mexico

    Irena Dujmovic,     Department for Immune-Mediated CNS Diseases, Clinic of Neurology, Clinical Centre of Serbia, Belgrade University School of Medicine, Belgrade, Serbia

    Marcelo Dutra Arbo,     Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal

    Scott Edwards,     Department of Physiology, Alcohol and Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, LA, USA

    Afshar Etemadi-Aleagha,     Department of Anesthesiology, Tehran University of Medical Sciences (TUMS), Amir Alam Hospital, Tehran, Iran

    Cuneyt Evren,     Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey

    Juan Fang,     Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China

    Camino Fernández-Rodríguez,     Servicio de Medicina Interna, Hospital Universitario de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Canary Islands, Spain

    Radmila Filipovic,     Physiology and Neurobiology Department, University of Connecticut, Storrs, CT, USA

    Josef Finsterer,     Krankenanstalt Rudolfstiftung, Vienna, Austria

    Megan L. Fitzgerald,     Department of Psychiatry, New York State Psychiatry Institute/Columbia University, New York, NY, USA

    Manoela V. Fogaça,     Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil

    Diego A. Forero,     Laboratory of NeuroPsychiatric Genetics, Biomedical Sciences Research Group, School of Medicine, Universidad Antonio Nariño, Bogotá, Colombia

    Hamdy Fouad Moselhy,     College of Medicine and Health Science, United Arab Emirates University, Alain City, UAE

    Marco Antonio de Freitas,     Instituto Médico Legal, Polícia Científica, Curitiba (PR), Brazil

    Cherrie Galletly,     The Adelaide Clinic, Gilberton, SA, Australia

    Borja García-Bueno,     Department of Pharmacology, Faculty of Medicine, University Complutense, Madrid, Spain

    Jodi M. Gatley

    Northern Medical Program, University of Northern British Columbia (UNBC), Prince George, BC, Canada

    Human Brain Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada

    Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    David Germanaud

    AP-HP, Robert-Debré Hospital, DHU PROTECT Department of Child Neurology, Paris, France

    CEA, NeuroSpin Center, UNIACT, Gif-sur-Yvette, France

    INSERM, UMR1129, Paris, France

    Roger S. Gifford

    Center for Drug Discovery (CDD), Northeastern University, Boston, MA, USA

    Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA

    Paul Glue,     Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Gabriella Gobbi,     Neurobiological Psychiatry Unit, McGill University, Montreal, QC, Canada

    Carlos Goicoechea,     A. Farmacología y Nutrición, Departamento de Ciencias Básicas de la Salud. Unidad Asociada de I+D+i al CSIC, Rey Juan Carlos University, Alcorcón, Madrid, Spain

    Emilio González-Arnay,     Departamento de Anatomía, Anatomía Patológica e Histología, Hospital Universitario de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Canary Islands, Spain

    Emilio González-Reimers,     Servicio de Medicina Interna, Hospital Universitario de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Canary Islands, Spain

    Rogelio González-Sarmiento

    Molecular Medicine Unit, Department of Medicine, University of Salamanca-IBSAL, Salamanca, Spain

    IBMCC, University of Salamanca-CSIC, Salamanca, Spain

    Linda Gowing,     Drug and Alcohol Services of South Australia, Discipline of Pharmacology, Medical School, The University of Adelaide, Adelaide, SA, Australia

    Kenneth L. Grieve,     Faculty of Life Sciences, University of Manchester, Manchester, UK

    Rubem Carlos Araújo Guedes,     Departamento de Nutrição, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil

    Consuelo Guerri,     Department of Cellular Pathology, Príncipe Felipe Research Centre, Valencia, Spain

    Francisco S. Guimarães,     Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil

    Leila Guller,     Department of Psychology, University of Kentucky, Lexington, KY, USA

    Jennifer Harland,     Discipline of Pharmacology, School of Medical Sciences, The University of Adelaide, Adelaide, SA, Australia

    Seyyed A. Hashemi,     Immunogenetic Research Center, Traditional and Complementary Medicine Research Center, Medical School Mazandaran University of Medical Sciences, Sari, Iran

    Shiva Hashemizadeh,     Department of Animal Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran

    Bei He,     Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China

    Salvador Hernández-López,     Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, México DF, México

    Tyson Hickle,     Department of Psychology, Creighton University, Omaha, NE, USA

    Shirley Y. Hill

    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA

    Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

    Joan Holgate,     Addiction Neuroscience and Obesity Group, Institute of Health and Biomedical Innovation, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD, Australia

    Wei Huang,     Center for Comparative NeuroImaging, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA

    Wei-Lieh Huang

    Department of Psychiatry, National Taiwan University Hospital, Douliou City, Yunlin County, Taiwan

    Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan

    Nicholas J. Hunt

    Department of Medicine, University of Sydney, Sydney, NSW, Australia

    The BOSCH Institute, University of Sydney, Sydney, NSW, Australia

    René Hurlemann,     Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany

    Giuseppe Iannone,     Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, Department of Clinical Neurosciences, Albese con Cassano, Italy

    Fariha Idrees,     Department of Chemistry, Islamia College University, Peshawar, Khyber Pakhtunkhwa, Pakistan

    Jawaria Idrees,     Department of Integrated Sciences, Post Graduate Nursing College, Peshawar, Khyber Pakhtunkhwa, Pakistan

    Kazutaka Ikeda,     Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

    Nato Ivanashvili,     Department of Public Health, Syracuse University, Tbilisi, Republic of Georgia

    Iliyan Ivanov,     Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Joseph L. Jacobson

    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA

    Departments of Human Biology and of Psychiatry and Mental Health, Faculty of Health Sciences, University of Cape Town, Detroit, MI, USA

    Sandra W. Jacobson

    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA

    Departments of Human Biology and of Psychiatry and Mental Health, Faculty of Health Sciences, University of Cape Town, Detroit, MI, USA

    Torbjörn U.C. Järbe

    Center for Drug Discovery (CDD), Northeastern University, Boston, MA, USA

    Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA

    Y.L. Jiang,     Department of Radiology, Kunming Medical University, Yunnan, China

    Farzaneh Jokar,     Department of Forensic Toxicology, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran

    Cynthia J.M. Kane,     Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Megan Kangiser,     Department of Psychology, Creighton University, Omaha, NE, USA

    Victor Karpyak,     Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA

    Jean A. King,     Center for Comparative NeuroImaging, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA

    Bronwyn M. Kivell,     School of Biological Sciences, Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand

    Eugene A. Kiyatkin,     Behavioral Neuroscience Branch, National Institute on Drug Abuse – Intramural Research Program, National Institutes of Health, DHHS, Baltimore, MD, USA

    Jochen Klein,     Department of Pharmacology, Goethe University Frankfurt, Frankfurt, Germany

    Michelle L. Klima,     Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    Sodikdjon A. Kodirov

    Department of General Physiology, Saint Petersburg University, Saint Petersburg, Russia

    Pavlov Institute of Physiology, Russian Academy of Sciences, Saint Petersburg, Russia

    Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, USA

    Institute of Experimental Medicine, I. P. Pavlov Department of Physiology, Russian Academy of Medical Sciences, Saint Petersburg, Russia

    Michal Korostynski,     Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

    Mary Jeanne Kreek,     The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA

    Svetlana Kulevanova,     Faculty of Pharmacy, Institute of Pharmacognosy, University Ss. Cyril and Methodius, Skopje, Republic of Macedonia

    Santosh Kumar,     Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Berthold Langguth,     Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany

    Mirna Bainy Leal,     Laboratório de Farmacologia e Toxicologia de Produtos Naturais, Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre (RS), Brazil

    Sheng-Yu Lee

    Department of Psychiatry, Kaohsiung Veteran’s Hospital, Kaohsiung, Taiwan

    Department of Psychiatry, College of Medicine, National Cheng Kung University

    Tatia M.C. Lee

    Laboratory of Neuropsychology, The University of Hong Kong, Pokfulam, Hong Kong

    Laboratory of Cognitive Affective Neuroscience, The University of Hong Kong, Pokfulam, Hong Kong

    Institute of Clinical Neuropsychology, The University of Hong Kong, Pokfulam, Hong Kong

    The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong

    John Leikaif,     Department of Psychiatry, Stanford University, Stanford, CA, USA

    Shih-Hsien Lin,     Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    Yu-Hsuan Lin,     Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan

    Xiu Liu,     Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA

    Valentina Lorenzetti

    Monash Clinical & Imaging Neuroscience, Monash University, Melbourne, VIC, Australia

    Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia

    Ru-Band Lu

    Department of Psychiatry, College of Medicine, National Cheng Kung University

    Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan

    Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    Addiction Research Center, National Cheng Kung University, Tainan, Taiwan

    Rita Machaalani

    Department of Medicine, University of Sydney, Sydney, NSW, Australia

    The BOSCH Institute, University of Sydney, Sydney, NSW, Australia

    The Children’s Hospital, Westmead, Sydney, NSW, Australia

    Antoniette Maldonado-Devincci,     Department of Psychiatry & Pharmacology, Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC, USA

    Jean-François Mangin,     CEA, NeuroSpin Center, UNATI, Gif-sur-Yvette, France

    Dimitra Mangoura,     Basic Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

    Patrick Manning,     Section of Endocrinology, Department of Internal Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Jahan P. Marcu

    Americans for Safe Access, Washington, DC, USA

    Green Standard Diagnostics, Inc., Las Vegas, NV, USA

    Simon McCabe,     Behavioural Science Centre, University of Stirling, Scotland, UK

    M. Adrienne McGinn,     Department of Physiology, Alcohol and Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, LA, USA

    Diana L. McKinney,     RD&E, Altria Client Services, Richmond, VA, USA

    Ryan McLaughin

    Neurobiological Psychiatry Unit, McGill University, Montreal, QC, Canada

    Department of Integrative Physiology and Neuroscience, College of Veterinary Medicine, Washington State University, Pullman, WA, USA

    Ian McLaughlin

    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Ernesta Meintjes,     MRC/UCT Medical Imaging Research Unit, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    Narasimha M. Midde,     Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Stefan Mihailescu,     Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, México DF, México

    José Miñarro,     Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de València, Valencia, Spain

    Raffaella Mondola,     Department of Mental Health, ASL CN1, Saluzzo, Italy

    A. Leslie Morrow,     Department of Psychiatry & Pharmacology, Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC, USA

    Nina R. Mota,     Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

    Jeffrey Newcorn,     Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Daisuke Nishizawa,     Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

    José N. Nobrega

    Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

    Campbell Family Mental Health Research Institute, Behavioural Neurobiology Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada

    Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Department of Psychology, University of Toronto, Toronto, ON, Canada

    Christina N. Nona

    Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

    Campbell Family Mental Health Research Institute, Behavioural Neurobiology Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada

    Nicolas Nuñez

    Neurobiological Psychiatry Unit, McGill University, Montreal, QC, Canada

    Hospital Neurospsiquiatrico de Agudos y Cronicos Dr. Alejandro Korn/Universidad, Nacional de La Plata, Buenos Aires, Argentina

    Ingrid Nylander,     Neuropharmacology, Addiction and Behaviour, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

    Jessica W. O’Brien

    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA

    Francesco Oliva,     Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Turin, Torino, Italy

    Sara Palm,     Neuropharmacology, Addiction and Behaviour, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

    Mauricio R. Papini,     Department of Psychology, Texas Christian University, Fort Worth, TX, USA

    Byung Lae Park,     Department of Genetic Epidemiology, SNP Genetics, Inc., Seoul, Republic of Korea

    María Pascual,     Department of Cellular Pathology, Príncipe Felipe Research Centre, Valencia, Spain

    Juan Pedraza,     Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Giampaolo Perna,     Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, Department of Clinical Neurosciences, Albese con Cassano, Italy

    Rocco Luigi Picci,     Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Turin, Torino, Italy

    Marcin Piechota,     Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

    Vladimir Pilija,     Institute of Forensic Medicine, Clinical Center Vojvodina, Novi Sad, Serbia

    Charles Pinto,     Department of Psychiatry, Jagjivanram Western Railways Hospital, Mumbai, Maharashtra, India

    Stéphane Potvin

    Department of Psychiatry, University of Montreal, Montreal, QC, Canada

    Centre de recherche de l’Institut universitaire en santé mentale de Montréal, Montreal, QC, Canada

    Jagdeo Prasad Rawat,     Department of Psychiatry, Jagjivanram Western Railways Hospital, Mumbai, Maharashtra, India

    Victor R. Preedy,     Diabetes and Nutritional Sciences Research Division, Faculty of Life Science and Medicine, King’s College London, London, UK

    Brittany M. Priddy,     NIH/NIDA, IRP/INRB, Baltimore, MD, USA

    Ryszard Przewlocki

    Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

    Department of Neurobiology and Neuropsychology, Institute of Applied Psychology, Jagiellonian University, Krakow, Poland

    Jimit G. Raghav

    Center for Drug Discovery (CDD), Northeastern University, Boston, MA, USA

    Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA

    Rajkumar Rajendram

    Department of Anaesthesia and Intensive Care, College of Medicine, King Khalid University Hospital, King Saud University Medical City, Riyadh, Saudi Arabia

    Diabetes and Nutritional Sciences Research Division, Faculty of Life Science and Medicine, King’s College London, London, UK

    Roshanna Rajendram,     Department of Emergency Medicine, The Royal Woolverhampton NHS Trust, New Cross Hospital, Wolverhampton, UK

    P.S.S. Rao,     Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Anirban Ray

    Department of Child and Adolescent Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India

    Department of Psychiatry, Calcutta National Medical College, Calcutta, West Bengal, India

    Ameneh Rezayof,     Department of Animal Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran

    Casto Rivadulla

    NEUROcom, Depto de Medicina, Univ da Coruña, Campus de Oza, A Coruña, Spain

    The Institute for Biomedical Research of Coruña (INIBIC), A Coruña, Spain

    Marta Rodríguez-Arias,     Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de València, Valencia, Spain

    Luciana Grazziotin Rossato,     Faculdade de Farmácia, Instituto de Ciências Biológicas, Universidade de Passo Fundo, Passo Fundo (RS), Brazil

    Diego L. Rovaris,     Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

    Christina L. Ruby,     Department of Biology, Indiana University of Pennsylvania, Indiana, PA, USA

    Nikos Sakellaridis,     Pharmacology Department, Medical School, University of Thessaly, Larissa, Greece

    Saad Salman,     Department of Psychiatry and Drug Detoxification Centre, Lady Reading Hospital, Post Graduate Medical Institute, Peshawar, Khyber Pakhtunkhwa, Pakistan

    Francisco Santolaria-Fernández,     Servicio de Medicina Interna, Hospital Universitario de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Canary Islands, Spain

    Siddharth Sarkar,     Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India

    Jason B. Schechter,     Cortical Systematics LLC, Tucson, AZ, USA

    André Schmidt,     Department of Psychiatry (UPK), University of Basel, Basel, Switzerland

    Susan Scholl,     Department of Public Health, Syracuse University, Syracuse, NY, USA

    April Scott,     University of Kentucky, Lexington, KY, USA

    Masroor Shariff,     Addiction Neuroscience and Obesity Group, Institute of Health and Biomedical Innovation, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD, Australia

    Shiwali Sharma,     Chitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India

    Hyoung Doo Shin,     Department of Life Science, Sogang University, Seoul, Republic of Korea

    Thakur Gurjeet Singh,     Chitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India

    Namita Sinha,     Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Patrick D. Skosnik

    Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA

    Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA

    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

    Ranilson de Souza Bezerra,     Departamento de Bioquímica,Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil

    Dustin J. Stairs,     Department of Psychology, Creighton University, Omaha, NE, USA

    Gjoshe Stefkov,     Faculty of Pharmacy, Institute of

    Enjoying the preview?
    Page 1 of 1